Protagonist Therapeutics (PTGX) Deferred Taxes (2019 - 2020)
Protagonist Therapeutics (PTGX) posted Deferred Taxes of $34000.0 for Q4 2020, up 525.0% sequentially from -$8000.0 in Q3 2020, and down 95.6% YoY from $773000.0 in Q1 2020.
Powered by 
Analysis
Protagonist Therapeutics (PTGX) Deferred Taxes (2019 - 2020) Analysis & Trends
Protagonist Therapeutics has reported Deferred Taxes for 2 years, with the latest figure at $34000.0 in Q4 2020.
- Quarterly Deferred Taxes fell 95.6% year-over-year to $34000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $1.4 million (up 285.55% YoY) and the FY2020 annual result came in at $1.4 million, up 285.55% from the prior year.
- Deferred Taxes climbed to $34000.0 in Q4 2020 per PTGX's latest filing, from -$8000.0 in the prior quarter.
- Over five years, Deferred Taxes peaked at $1.2 million in Q2 2020 and troughed at -$1.6 million in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Protagonist Therapeutics | 9.61 Bn | 9.61 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2020 | 34,000.00 |
| Sep 30, 2020 | -8,000.00 |
| Jun 30, 2020 | 1.23 Mn |
| Mar 31, 2020 | 183,000.00 |
| Dec 31, 2019 | 773,000.00 |
| Sep 30, 2019 | -102,000.00 |
| Jun 30, 2019 | -1.63 Mn |
| Mar 31, 2019 | 180,000.00 |